PRTC News and Press, PureTech Health plc From 03/18/24

Acquisition centered on KarXT, which was invented at PureTech, as a potential first-in-class treatment for schizophrenia in adults PureTech to receive approximately $293 million gross proceeds from Karuna equity position in addition to being eligible for further milestones and royalty pay...

LYT-200 is being advanced in hematological malignancies such as acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), and locally advanced/metastatic solid tumors, including head and neck cancers Phase 1b clinical trial evaluating LYT-200 in relapsed/refractory AML an...

Japanese Product Now Under Review for Nationwide Marketing Approval PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Ent...

2024-02-03 09:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that Daphne Zohar, Founder and Chief Executive Officer, will present at the 42 nd Annu...

2023-12-30 06:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-20 03:15:16 ET More on PureTech PureTech Phase 2 study for anti-anxiety drug LYT-300 meets primary endpoint Seeking Alpha’s Quant Rating on PureTech Historical earnings data for PureTech Financial information for PureTech For further de...

Strong strategic and clinical progress in 2023, with multiple catalysts expected in 2024 Launching of two new Founded Entities to advance certain programs from the Wholly Owned Pipeline Robust balance sheet position with estimated Consolidated Cash, Cash Equivalents and Short-Term...

LYT-200 demonstrates favorable safety profile and anti-tumor activity in combination with anti-PD-1 agent, tislelizumab Three out of four patients treated so far with head and neck cancers experienced disease control, with one complete response and one partial response observed in the fir...

Prescription Drug User Fee Act (PDUFA) action date is September 26, 2024 If approved, KarXT would represent the first new pharmacological approach to treating schizophrenia in several decades The application is supported by positive data from the EMERGENT clinical trial program sh...